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Pathological gambling and dopamine agonists: A phenotype?
Therapeutic dopamine agonists have been around a long time ever since the deﬁ  cit of 
brain dopamine in Parkinson’s disease (PD) was ﬁ  rst reported in 1960 (Ehringer and 
Hornykiewicz 1960) swiftly followed by the ﬁ  rst clinical trial of levodopa adminis-
tration in Parkinsonian patients (Birkmayer and Hornykiewicz 1961). Design of new 
dopamine agonists was also a ﬁ  rst love of the Editor of Neuropsychiatric Disease 
and Treatment (Pinder 1970; Miller et al 1974). In those ﬁ  rst heady years efﬁ  cacy 
in a previously untreatable but rather common neurological disorder seemed more 
important than side effects, especially as more selective agonists of dopamine than 
levodopa came on stream. Indeed, in addition to the many variations on levodopa, 
such as different pharmaceutical formulations and various combinations with enzyme 
inhibitors, there is now an armamentarium of such drugs available including ergoline 
derivatives like bromocriptine, cabergoline, and pergolide and non-ergolines such as 
pramipexole, ropinirole, and rotigotine. Dopamine agonists are even being used as 
monotherapy in early PD before levodopa-containing drugs are considered (Clarke 
and Guttman 2002).
Cabergoline and pergolide have recently been associated with an increased risk of 
valvular heart disease in PD patients (Schade et al 2007; Zanettini et al 2007), because 
of these ﬁ  ndings, pergolide was recently withdrawn from the US market by the FDA. 
Among the many side effects of all dopamine agonists as treatments for PD are impulse 
control disorders such as pathological gambling (Driver-Dunckley et al 2003; Dodd 
et al 2005). Although serious, and often ﬁ  nancially and socially catastrophic for the 
individual patient, compulsive gambling is relatively uncommon and the predictive 
features for determining who is likely to experience impulsive behavior are unknown. 
However, in this issue, the group of Hubert Fernandez at the McKnight Brain Institute 
at the University of Florida proposes a possible ‘phenotype’ based on the four As: 
anxiety, anger, age, and agonists (Shapiro et al 2007). They have analyzed whether 
lifestyle or environmental factors are associated with pathological gambling in PD. 
Although the sample is relatively small, compulsive gamblers appear to be younger 
and exhibit higher levels of anxiety, anger, and confusion. A Canadian report has 
also been published in February with a somewhat larger sample, which conﬁ  rms the 
younger age of compulsive gamblers and the use of dopamine agonists, together with 
a history of medication-induced hypomania or mania, higher novelty seeking, and a 
personal or immediate family history of alcohol use disorders (Voon et al 2007). If these 
vulnerabilities can be conﬁ  rmed in larger and longer-term studies, particularly in other 
PD populations across the globe, then we may be able to talk about a true phenotype. 
Identiﬁ  cation of PD patients potentially at risk for developing compulsive gambling 
behavior would be particularly useful to clinicians prescribing dopamine agonists 
enabling them to be extra vigilant when dealing with this particular sub-population.
Dopamine agonists are also used in another chronic neurological disorder, restless 
legs syndrome (RLS), despite the lack of a precise dopaminergic pathophysiology 
for the disorder (Happe and Trenkwalder 2004; Trenkwalder et al 2005). The last 
issue of Neuropsychiatric Disease and Treatment was largely devoted to RLS, and 
included major reviews on RLS-associated disturbances of sleep (Bogan 2006) and 
mood (Becker 2006), evaluations of pramipexole (Benbir and Guilleminault 2006), 
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ropinirole (Kushida 2006) and rotigotine (Bunten and Happe 
2006), and an accompanying editorial (Pinder 2006). Now the 
ﬁ  rst cases of pathological gambling in 3 patients with RLS 
under treatment with dopamine agonists mainly pramipexole 
have been reported (Tippmann-Peikert et al 2007). Except for 
age and medication, it is not clear whether the RLS patients 
ﬁ  t into the Fernandez phenotype being proposed for PD. It is 
likely that the triggers for pathological gambling associated 
with dopamine agonist therapy are similar in RLS and PD, 
and that ultimately there may be some degree of commonality 
in the pathophysiology of the two disorders.
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